GLP-1 receptor agonists

The Biden administration unveils a groundbreaking proposal to extend Medicare and Medicaid coverage to popular weight-loss drugs such as Wegovy and Ozempic, marking a significant shift in federal healthcare policy. This rule aims to provide millions of Americans living with obesity access to treatments previously deemed too expensive for many to afford out-of-pocket.

The proposal, introduced Tuesday morning, seeks to address the growing obesity epidemic that affects over 40% of adults in the United States. Wegovy and Ozempic, manufactured by Novo Nordisk, are glucagon-like peptide-1. . .